Sponsor content
330 result(s) found, displaying 131 to 140
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Australian public assessment report (AusPar)Enhertu (trastuzumab deruxtecan) for treatment of unresectable or metastatic HER2 positive breast cancer.
-
Designation or determinationPriority review
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Budesonide / glycopyrronium / formoterol
-
Prescription medicine decision summaryTGA Decision: Saphnelo (anifrolumab) is approved to treat adult patients with active systemic lupus erythematosus (SLE).